BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
A. Zullo, F. Cristofari, C. Hassan. H. pylori should be eradicated in chronic liver disease patients with peptic ulcerDigestive and Liver Disease 2009; 41(2): 141 doi: 10.1016/j.dld.2008.11.004
2
Chung-Chuan Chan, Nai-Hsuan Chien, Chia-Long Lee, Yi-Chen Yang, Chih-Sheng Hung, Tien-Chien Tu, Chi-Hwa Wu. Comparison of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori eradication in inactive peptic ulcer disease and the efficiency of sequential therapy in inactive peptic ulcer disease and non-ulcer dyspepsiaBMC Gastroenterology 2015; 15(1) doi: 10.1186/s12876-015-0401-4
3
Byoung Hwan Lee, Nayoung Kim, Tae Jun Hwang, Sang Hyub Lee, Young Soo Park, Jin-Hyeok Hwang, Jin-Wook Kim, Sook-Hyang Jeong, Dong Hoo Lee, Hyun Chae Jung, In Sung Song. Bismuth-Containing Quadruple Therapy as Second-Line Treatment forHelicobacter pyloriInfection: Effect of Treatment Duration and Antibiotic Resistance on the Eradication Rate in KoreaHelicobacter 2010; 15(1): 38 doi: 10.1111/j.1523-5378.2009.00735.x
4
Swanson's Family Medicine Review: A Problem-Oriented Approach2013; : 168 doi: 10.1016/B978-1-4557-0790-4.00032-9
5
Emad M El-Omar. What is the optimal therapy for the eradication of Helicobacter pylori?Nature Clinical Practice Gastroenterology & Hepatology 2006; 3(3): 126 doi: 10.1038/ncpgasthep0422
6
Seiji Shiota, Lam Tung Nguyen, Kazunari Murakami, Akiko Kuroda, Kazuhiro Mizukami, Tadayoshi Okimoto, Masaaki Kodama, Toshio Fujioka, Yoshio Yamaoka. Association of Helicobacter pylori dupA With the Failure of Primary EradicationJournal of Clinical Gastroenterology 2012; 46(4): 297 doi: 10.1097/MCG.0b013e318243201c
7
W. Nseir, J. Mograbi. Commentary: simvastatin as the key to improving H. pylori eradication rates? Authors’ replyAlimentary Pharmacology & Therapeutics 2012; 36(5): 494 doi: 10.1111/j.1365-2036.2012.05216.x
8
A. ZULLO, F. PERNA, C. HASSAN, C. RICCI, I. SARACINO, S. MORINI, D. VAIRA. Primary antibiotic resistance in Helicobacter pylori strains isolated in northern and central ItalyAlimentary Pharmacology & Therapeutics 2007; 25(12): 1429 doi: 10.1111/j.1365-2036.2007.03331.x
9
Hilmi Ataseven, Mehmet Demir, Ramazan Gen. Effect of Sequential Treatment as a First-Line Therapy for Helicobacter pylori Eradication in Patients with Diabetes MellitusSouthern Medical Journal 2010; 103(10): 988 doi: 10.1097/SMJ.0b013e3181eea6cc
10
Xavier Calvet, Javier P. Gisbert, David Suarez. Key Points for Designing and Reporting Helicobacter pylori Therapeutic Trials: A Personal ViewHelicobacter 2011; 16(5): 346 doi: 10.1111/j.1523-5378.2011.00890.x
11
Lyudmila Boyanova, Juliana Ilieva, Galina Gergova, Zoya Spassova, Rossen Nikolov, Lubomir Davidkov, Ivailo Evstatiev, Victor Kamburov, Nikolai Katsarov, Ivan Mitov. Evaluation of clinical and socio-demographic risk factors for antibacterial resistance of Helicobacter pylori in Bulgaria Journal of Medical Microbiology 2009; 58(1): 94 doi: 10.1099/jmm.0.003855-0
12
Angelo Zullo, Cesare Hassan, Alessandro Andriani, Francesca Cristofari, Vincenzo De Francesco, Enzo Ierardi, Silverio Tomao, Sergio Morini, Dino Vaira. Eradication Therapy for Helicobacter pylori in Patients With Gastric MALT Lymphoma: A Pooled Data AnalysisThe American Journal of Gastroenterology 2009; 104(8): 1932 doi: 10.1038/ajg.2009.314
13
Yuhong Yuan, Alex C Ford, Khurram J Khan, Javier P Gisbert, David Forman, Grigorios I Leontiadis, Frances Tse, Xavier Calvet, Carlo Fallone, Lori Fischbach, Giuseppina Oderda, Franco Bazzoli, Paul Moayyedi. Optimum duration of regimens forHelicobacter pylorieradicationCochrane Database of Systematic Reviews 2013;  doi: 10.1002/14651858.CD008337.pub2